Abstract
To assess an effect of vaccination on the level of humoral anti-influenza herd immunity, 2955 sera were collected and analyzed by HIT in the 2019–2020 and 2020–2021 epidemiological seasons. All sera were obtained from healthy adult donors residing in various cities of the Russian Federation. Among them, 1057 volunteers were vaccinated with seasonal influenza trivalent inactivated vaccine. Characteristics of humoral anti-influenza immunity (average geometric antibody titers and the proportion of individuals seropositive for the vaccine viruses) obtained in autumn 2019 and 2020 (1–2 months after vaccination) in vaccinated individuals vs. unvaccinated subjects were found to be markedly higher evidencing about a positive vaccination-related contribution to developing herd immunity against influenza in the preepidemic periods. After the 2019–2020 influenza epidemic, in spring 2020 (6–7 months after vaccination), the levels of antibodies to all vaccine components decreased by 2.6–3.5-fold in vaccinated donors compared to the pre-epidemic period in 2019 autumn. Antibody titers became substantially lower than the protective level (titer by HIT 1/40). At the same time, no significant differences between the groups of vaccinated vs. unvaccinated individuals were observed afterwards. This indicates instability of post-vaccination anti-influenza humoral immunity. As a result, it may decrease an influenza-resistant population cohort of working age on the eve of new epidemic season. The immunogenicity of the inactivated trivalent seasonal influenza vaccine was estimated by HIT while analyzing paired sera obtained from 295 and 112 healthy individuals of various ages vaccinated in autumn 2019 and 2020, respectively. The response to the vaccine was found to be age-related. Children aged 3–14 years vs. older subjects showed a more efficient response. Insufficient immunogenicity of influenza B virus vaccine components was shown. In all age groups, average geometric titers for influenza B virus antibodies were lower (2–8-fold) than for current A(H1N1)pdm09-like strains and influenza A(H3N2) viruses 1–1.5 months post-vaccination. Analyzing vaccine immunogenicity showed a significant inverse relationship between the level of preexisting strain-specific serum antibodies before vaccination and formation of antibodies to the corresponding vaccine virus 1–1.5 months after vaccination. Seroconversion to each vaccine component was remarkably more frequent in individuals with a low preexisting level of antibodies specific to the corresponding virus.
Highlights
Вакцинация считается наиболее эффективным способом борьбы с гриппом и оказывает двойной эффект: прямой и опосредованный
Immunogenicity of the trivalent inactivated influenza A virus vaccine for children and adults vaccinated in autumn 2019
Immunogenicity of the trivalent inactivated influenza B virus vaccine for children and adults vaccinated in autumn 2019
Summary
ВЛИЯНИЕ ВАКЦИНАЦИИ ПРОТИВ ГРИППА НА УРОВЕНЬ СПЕЦИФИЧЕСКОГО ГУМОРАЛЬНОГО ИММУНИТЕТА ЗДОРОВЫХ ЛИЦ. Для оценки влияния вакцинации на уровень гуморального популяционного противогриппозного иммунитета методом РТГА были проанализированы 2955 сывороток здоровых взрослых доноров, полученных из различных городов Российской Федерации в эпидсезоны 2019–2020 и 2020–2021 гг. Значительно более высокие показатели гуморального противогриппозного иммунитета у привитых лиц по сравнению с невакцинированными (средние геометрические титры антител и доля серопозитивных лиц по отношению к вакцинным вирусам), полученные осенью 2019 и 2020 гг. Помимо влияния вакцинации на состояние популяционного иммунитета взрослого населения России, в РТГА была оценена иммуногенность инактивированной трехвалентной сезонной вакцины по результатам анализа парных сывороток, полученных от 295 и 112 здоровых лиц различного возраста, привитых осенью 2019 г. Для цитирования: Кривицкая В.З., Кузнецова Е.В., Майорова В.Г., Петрова Е.Р., Соминина А.А., Даниленко Д.М. Влияние вакцинации против гриппа на уровень специфического гуморального иммунитета здоровых лиц // Инфекция и иммунитет.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.